Advertisement

Radical Surgery in Ovarian Cancer

  • Deepa Maheswari Narasimhulu
  • Fady Khoury-Collado
  • Dennis S. ChiEmail author
Gynecologic Cancers (NS Reed, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gynecologic Cancers

Abstract

While there is an ongoing debate regarding the timing of the maximal surgical effort in epithelial ovarian cancer, it is well established that patients with suboptimal tumor debulking derive no benefit from the surgical procedure. The amount of residual disease after cytoreductive surgery has been repeatedly identified as a strong predictor of survival, and accordingly, the surgical effort to achieve the goal of complete gross tumor resection has been constantly evolving. Centers that have adopted the concept of radical surgery in patients with advanced ovarian cancer have reported improvements in their patients’ survival. In addition to the expected improvements in the pharmacologic treatment of this disease, some of the next challenges in the surgical management of ovarian cancer include the preoperative prediction of suboptimal debulking, improving the drug delivery to the tumor, and increasing access to centers of excellence in ovarian cancer regardless of geographical, financial, or other social barriers. This review will discuss an update on the role of surgery in the treatment of primary epithelial ovarian cancer as it has evolved since the emergence of the concept of surgical cytoreduction.

Keywords

Epithelial ovarian cancer Cytoreductive surgery Survival Residual tumor Tumor debulking 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Deepa Maheswari Narasimhulu, Fady Khoury-Collado, and Dennis S. Chi declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.CrossRefPubMedGoogle Scholar
  3. 3.
    Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol. 2012;125(2):483–92.CrossRefPubMedGoogle Scholar
  4. 4.
    Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.CrossRefPubMedGoogle Scholar
  5. 5.
    Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–4.PubMedGoogle Scholar
  6. 6.
    Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol. 2000;78(3 Pt 1):269–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol. 2001;82(3):489–97.CrossRefPubMedGoogle Scholar
  9. 9.
    Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103(2):559–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Winter 3rd WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(24):3621–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234–44.CrossRefPubMedGoogle Scholar
  13. 13.
    Peiretti M, Zanagnolo V, Aletti GD, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010;119(2):259–64.CrossRefPubMedGoogle Scholar
  14. 14.
    Kommoss S, Rochon J, Harter P, et al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol. 2010;17(1):279–86.CrossRefPubMedGoogle Scholar
  15. 15.
    Wimberger P, Wehling M, Lehmann N, et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol. 2010;17(6):1642–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Harter P, Muallem ZM, Buhrmann C, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121(3):615–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19(13):4059–67.CrossRefPubMedGoogle Scholar
  18. 18.
    Wright JD, Lewin SN, Deutsch I, et al. Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2011;123(3):467–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Wright JD, Herzog TJ, Neugut AI, et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol. 2012;120(4):871–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Aletti GD, Eisenhauer EL, Santillan A, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120(1):23–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Chi DS, Zivanovic O, Levinson KL, et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 2010;119(1):38–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Hoffman MS, Zervose E. Colon resection for ovarian cancer: intraoperative decisions. Gynecol Oncol. 2008;111(2 Suppl):S56–65.CrossRefPubMedGoogle Scholar
  24. 24.
    Silver DF, Bou ZN. Extended left colon resections as part of complete cytoreduction for ovarian cancer: tips and considerations. Gynecol Oncol. 2009;114(3):427–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Song YJ, Lim MC, Kang S, et al. Total colectomy as part of primary cytoreductive surgery in advanced Müllerian cancer. Gynecol Oncol. 2009;114(2):183–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Shimada M, Kigawa J, Minagawa Y, Irie T, et al. Significance of cytoreductive surgery including bowel resection for patients with advanced ovarian cancer. Am J Clin Oncol. 1999;22(5):481–4.CrossRefPubMedGoogle Scholar
  27. 27.
    Mourton SM, Temple LK, Abu-Rustum NR, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005;99(3):608–14.CrossRefPubMedGoogle Scholar
  28. 28.
    Estes JM, Leath 3rd CA, Straughn Jr JM, et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg. 2006;203(4):527–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Aletti GD, Podratz KC, Jones MB, et al. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg. 2006;203(4):521–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Tebes SJ, Cardosi R, Hoffman MS. Colorectal resection in patients with ovarian and primary peritoneal carcinoma. Am J Obstet Gynecol. 2006;195(2):585–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Park JY, Seo SS, Kang S, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006;103(3):977–84.CrossRefPubMedGoogle Scholar
  32. 32.
    Salani R, Zahurak ML, Santillan A, et al. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 2007;107(3):495–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Kalogera E, Dowdy SC, Mariani A, et al. Multiple large bowel resections: potential risk factor for anastomotic leak. Gynecol Oncol. 2013;130(1):213–8.CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Hamilton CA, Miller A, Miller C, et al. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122(3):521–6.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Cliby W, Dowdy S, Feitoza SS, et al. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol. 2004;94(3):655–60.CrossRefPubMedGoogle Scholar
  36. 36.
    Eisenkop SM, Spirtos NM, Lin WC. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol Oncol. 2006;100(2):344–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Magtibay PM, Adams PB, Silverman MB, et al. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol. 2006;102(2):369–74.CrossRefPubMedGoogle Scholar
  38. 38.
    Dowdy SC, Loewen RT, Aletti G, et al. Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol. 2008;109(2):303–7.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Martinez A, Pomel C, Mery E, et al. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2011;121(2):258–63.CrossRefPubMedGoogle Scholar
  40. 40.
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103(3):1083–90.CrossRefPubMedGoogle Scholar
  41. 41.
    Zivanovic O, Sima CS, Iasonos A, et al. The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecol Oncol. 2010;116(3):351–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Juretzka MM, Abu-Rustum NR, Sonoda Y, et al. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol Oncol. 2007;104(3):670–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Cohen-Mouly S, Badia A, Bats AS, et al. Role of video-assisted thoracoscopy in patients with ovarian cancer and pleural effusion. Int J Gynecol Cancer. 2009;19(9):1662–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Diaz JP, Abu-Rustum NR, Sonoda Y, et al. Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol Oncol. 2010;116(3):483–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Mironov O, Sala E, Mironov S, et al. Thoracic metastasis in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery. J Gynecol Oncol. 2011;22(4):260–8.CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Klar M, Farthmann J, Bossart M, et al. Video-assisted thoracic surgery (VATS) evaluation of intrathoracic disease in patients with FIGO III and IV stage ovarian cancer. Gynecol Oncol. 2012;126(3):397–402.CrossRefPubMedGoogle Scholar
  47. 47.
    Eitan R, Levine DA, Abu-Rustum N, et al. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer. 2005;103(7):1397–401.CrossRefPubMedGoogle Scholar
  48. 48.
    Mironov O, Ishill NM, Mironov S, et al. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival. Radiology. 2011;258(3):776–84.CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Aletti GD, Podratz KC, Cliby WA, et al. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol. 2009;112(1):22–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Perri T, Ben-Baruch G, Kalfon S, et al. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction? Gynecol Oncol. 2013;131(1):27–31.CrossRefPubMedGoogle Scholar
  51. 51.•
    Suidan RS, Ramirez PT, Sarasohn DM, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134(3):455–61. Efforts to try to predict preoperatively surgical outcome may allow avoiding unnecessary surgery in patients with high likelihood of suboptimal debulking.Google Scholar
  52. 52.
    Giovanella BC, Stehlin Jr JS, Morgan AC. Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res. 1976;36:3944–50.PubMedGoogle Scholar
  53. 53.
    Engin K. Biological rationale for hyperthermia in cancer treatment (II). Neoplasma. 1994;41(5):277–83.PubMedGoogle Scholar
  54. 54.
    Pölcher M, Zivanovic O, Chi DS. Cytoreductive surgery for advanced ovarian cancer. Womens Health. 2014;10(2):179–90.Google Scholar
  55. 55.
    Chua TC, Robertson G, Liauw W, et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135:1637–45.CrossRefPubMedGoogle Scholar
  56. 56.•
    Zivanovic O, Abramian A, Kullmann M, et al. HIPEC ROC I: a phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2015;136(3):699–708. It is important to study HIPEC in the setting of well designed clinical trials and not extrapolate from heterogeneous single institution retrospective series.Google Scholar
  57. 57.••
    Bristow RE, Chang J, Ziogas A, et al. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol. 2014;132(2):403–10. It is important to study and remove the barriers to access appropriate surgical care for ovarian cancer at the time as we continue to improve that standard.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Deepa Maheswari Narasimhulu
    • 1
  • Fady Khoury-Collado
    • 1
  • Dennis S. Chi
    • 2
    • 3
    Email author
  1. 1.Gynecologic Oncology DivisionMaimonides Medical CenterBrooklynUSA
  2. 2.Gynecology Service, Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA
  3. 3.Department of Obstetrics and GynecologyWeill Cornell Medical CenterNew YorkUSA

Personalised recommendations